Validation of Superiority of p40 over p63 in Differentiating Squamous Cell Carcinoma and Adenocarcinoma Lung
Open Access
- 1 July 2020
- journal article
- research article
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 41 (04), 535-542
- https://doi.org/10.4103/ijmpo.ijmpo_51_19
Abstract
In this era of targeted therapy, it is important to distinguish the various subtypes of nonsmall cell lung carcinoma (NSCC). Diagnosis based on morphology alone is challenging in poorly differentiated carcinomas and core biopsies. Immunohistochemistry (IHC) helps in specifying the lineage for the subtype of NSCC. Till date, p63 is the most frequently used and sensitive marker for squamous cell carcinoma (SQCC). However, it is not specific and stains a subset of adenocarcinoma (ADC). Thus, a more reliable and specific marker is required for the diagnosis of SQCC. The objective of the study was to validate the diagnostic utility of p40 over p63 in differentiating pulmonary SQCC from ADC and NSCC-not otherwise specified (NOS). A total of 123 cases of NSCC were initially reviewed and subtyped blinded to the results of IHC. This was followed by a review of IHC slides which included p63, p40, thyroid transcription factor 1, Napsin-A, cytokeratin (CK) 5/6, and CK7. There were 64 ADC, 19 SQCC, and 40 NSCC-NOS. IHC helped to confirm the morphological diagnosis in 62/64 ADCs and19/19 SQCCs. IHC classified the cases of NSCC-NOS into NSCC favoring ADC – 12 cases, NSCC favoring SQCC – 10 cases, and NSCC favoring AD-SQCC – 4 cases. Both p63 and p40 showed near equal sensitivity for SQCC (100% and 97%, respectively), whereas p63 showed far lower specificity when compared to p40 (51.3% vs. 100%). The present study confirms and validates that p40 is equally sensitive but highly specific than p63 in detecting SQCC. Hence, we recommend the routine use of p40 instead of p63 for the definite categorization of NSCC of the lung. Received: 26 February 2019 Accepted: 29 June 2020 Publication Date: 17 May 2021 (online) © 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, IndiaKeywords
This publication has 13 references indexed in Scilit:
- An Immunohistochemical Analysis of a Newly Developed, Mouse Monoclonal p40 (BC28) Antibody in Lung, Bladder, Skin, Breast, Prostate, and Head and Neck CancersArchives of Pathology & Laboratory Medicine, 2014
- Utilization of p40 (ΔNp63) with p63 and Cytokeratin 5/6 Immunohistochemistry in Non-Small Cell Lung Carcinoma Fine-Needle Aspiration BiopsyActa Cytologica, 2013
- Genetic alterations defining NSCLC subtypes and their therapeutic implicationsLung Cancer, 2013
- A Study of ΔNp63 Expression in Lung Non-Small Cell CarcinomasThe American Journal of Surgical Pathology, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinomaLaboratory Investigation, 2011
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung AdenocarcinomaJournal of Thoracic Oncology, 2011
- Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine‐needle aspiration cytologyCancer, 2011
- Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology: A Paradigm ShiftJournal of Thoracic Oncology, 2010
- Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapyNature Clinical Practice Oncology, 2006